|
1
|
Circulating microRNAs as stable blood-based markers for cancer detection.
|
Proc Natl Acad Sci U S A
|
2008
|
33.65
|
|
2
|
Development of an ovarian cancer symptom index: possibilities for earlier detection.
|
Cancer
|
2007
|
4.76
|
|
3
|
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries.
|
PLoS One
|
2009
|
2.37
|
|
4
|
Systematic evaluation of candidate blood markers for detecting ovarian cancer.
|
PLoS One
|
2008
|
1.93
|
|
5
|
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition.
|
Gynecol Oncol
|
2009
|
1.84
|
|
6
|
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.
|
Gynecol Oncol
|
2009
|
1.77
|
|
7
|
Digital genomic quantification of tumor-infiltrating lymphocytes.
|
Sci Transl Med
|
2013
|
1.72
|
|
8
|
Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.
|
PLoS One
|
2008
|
1.72
|
|
9
|
DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines.
|
PLoS One
|
2010
|
1.65
|
|
10
|
ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma.
|
PLoS Biol
|
2011
|
1.53
|
|
11
|
Bead-based ELISA for validation of ovarian cancer early detection markers.
|
Clin Cancer Res
|
2006
|
1.52
|
|
12
|
Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
1.52
|
|
13
|
Adequate staging for uterine cancer can be performed through Pfannenstiel incisions.
|
Gynecol Oncol
|
2003
|
1.41
|
|
14
|
Potential role of HE4 in multimodal screening for epithelial ovarian cancer.
|
J Natl Cancer Inst
|
2011
|
1.39
|
|
15
|
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
|
J Clin Oncol
|
2006
|
1.31
|
|
16
|
Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels.
|
Mol Cell Proteomics
|
2005
|
1.30
|
|
17
|
Robotic surgery in gynecologic oncology: program initiation and outcomes after the first year with comparison with laparotomy for endometrial cancer staging.
|
Am J Obstet Gynecol
|
2008
|
1.24
|
|
18
|
Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
|
Cancer Epidemiol Biomarkers Prev
|
2009
|
1.16
|
|
19
|
Early diagnosis of ovarian carcinoma: is a solution in sight?
|
Radiology
|
2011
|
1.16
|
|
20
|
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.
|
Gynecol Oncol
|
2009
|
1.14
|
|
21
|
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.
|
Cancer Prev Res (Phila)
|
2011
|
1.10
|
|
22
|
An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription.
|
Nucleic Acids Res
|
2011
|
1.08
|
|
23
|
Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma.
|
Obstet Gynecol
|
2002
|
1.07
|
|
24
|
Surgical outcomes in gynecologic oncology in the era of robotics: analysis of first 1000 cases.
|
Am J Obstet Gynecol
|
2011
|
1.06
|
|
25
|
Changes in cancer worry associated with participation in ovarian cancer screening.
|
Psychooncology
|
2007
|
1.04
|
|
26
|
Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers.
|
OMICS
|
2009
|
0.98
|
|
27
|
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2012
|
0.97
|
|
28
|
Dangerous combinations: Ingestible CAM supplement use during chemotherapy in patients with ovarian cancer.
|
J Altern Complement Med
|
2013
|
0.96
|
|
29
|
Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model.
|
Clin Cancer Res
|
2014
|
0.89
|
|
30
|
Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.87
|
|
31
|
Involvement in decision-making about treatment and ovarian cancer survivor quality of life.
|
Gynecol Oncol
|
2011
|
0.81
|
|
32
|
Clear cell adenocarcinoma of the vagina in a patient with vaginal endometriosis.
|
Gynecol Oncol
|
2006
|
0.81
|
|
33
|
Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer.
|
Gynecol Oncol
|
2003
|
0.75
|